Eradivir

Eradivir is a private, preclinical-stage biotech founded in 2020 by renowned drug developer Dr. Philip S. Low. The company's core technology, the BAiT platform, uses small molecules to bridge diseased cells and the innate immune system, aiming for a precise and potent therapeutic effect. With a seasoned leadership team and a validated founder track record, Eradivir is advancing its lead candidate, EV25, for influenza and exploring applications in other diseases like cancer. The company represents a novel approach in immunotherapy, leveraging the advantages of small molecules to potentially overcome limitations of biologic therapies.

Bispecific Antigenic immuno-Therapy (BAiT) platform: small molecules that bind diseased cells via a targeting ligand and recruit endogenous anti-hapten antibodies to trigger immune destruction.

In influenza, Eradivir competes with approved neuraminidase inhibitors, polymerase inhibitors, and developers of universal vaccines. In immuno-oncology, it would face intense competition from approved and pipeline bispecific antibodies, antibody-drug conjugates, and cell therapies. Its key differentiator is the small molecule bispecific format.